WHEN SHOULD NSAIDs BE USED?
NSAIDs are used primarily to control pain, stiffness, and reduce inflammation. They are one of the first line treatments in the care of clients with osteoarthritis and rheumatoid arthritis which together affect approximately 25 million clients in the United States. Other common indications are: • Fibromyalgia. • Connective tissue diseases. • Spondarthropathies. • Gout/pseudogout. • Musculoskeletal problems (bursitis/tendinitis). • Primary dysmenorrhea. • Systemic lupus erythematosus.
Unlabeled uses of NSAIDs also exist. These uses include migraines, sunburns, and premenstrual syndrome. Also, one of the latest studies suggested NSAIDs help the brain fight the effects of amyloid protein deposits linked to Alzheimer's. In a 14 year Johns Hopkins University study of 2,065 elderly people, participants given NSAIDs were 30% to 60% less likely to develop Alzheimer's compared with participants using other pain relievers or no drugs at all (Stewart, 1997) .
PHARMACOKINETICS
All NSAIDs are rapidly absorbed following oral administration. Various factors (food and dosage formulations such as enteric coated or delayed release) may delay rate of absorption, but extent of absorption generally remains unaffected. Peak concentrations can be Herfindal ( 1992) detected in the serum 15 minutes to 2 hours after oral administration, depending on the dosage form and specific formulations . However, maximum therapeutic effects may not be attained for 2 to 3 weeks after starting therapy.
All NSAIDs are highly protein bound (>90%), primarily to albumin. They are metabolized chiefly by hepatic bio-transformation and excreted primarily through the kidneys. The half life of NSAIDs varies from 1 to 20 to 25 hours after ingestion of a single dose.
Half life refers to the time required for the serum concentration of a drug to be decreased by one half (Herfindal, 1992) .
MECHANISM OF ACTION
The ability of NSAIDs to exert analgesic and antiinflammatory effects is mediated by two mechanisms. First, NSAIDs control inflammation by inhibiting the synthesis of prostaglandin, an inflammatory mediator generated at the site of tissue injury. NSAIDs inhibit prostaglandin H synthetase (cyclo-oxygenase or COX), responsible for converting arachidonic acid to prostaglandins, which mediate inflammation. Through this mediation , nerves are sensitized to painful stimuli with edema, cellular exudation, and pain resulting.
Two isoforms are prostaglandin H synthetase I (PGHS-l) and prostaglandin H synthetase 2 (PGHS-2). PGHS-l enzyme is always present and found in most tissues. It maintains the integrity of gastric and duodenal mucosa. Enzyme inhibition leads to adverse gastrointestinal effects of NSAID s, i.e., loss of the protective action of prostaglandin in the gastric mucosa. PGHS-2 enzyme is normally undetectable and is induced during inflammatory states. PGHS-2 enzyme increases inflammation by promoting synthesis of inflammatory mediators. Current NSAIDs inhibit both PGHS-l and PGHS-2. Future NSAIDs may selectively inhibit PGHS-2, but currently no NSAID demonstrates selective PGHS-2 inhibition (DeWitt, 1993) .
The second mechani sm by which NSAIDs exert analgesic and antiinflammatory effects is through the inhibition of leukatrine B4 production. Leukatrine B4 draws neutrophils to the sites of inflammation . Thus, by decreasing the migration of neutrophils to inflammatory sites, the release of free radicals and destructive enzymes at these sites is minimized (Conaway, 1995) .
SPECIFIC AGENTS
Selection of an NSAID should be based on the client's health history (for example , allergie s, other medications used, and the presence of other illnesses [e.g., hypertension, kidney disease]), efficacy, safety (e.g., side effects), tolerability, pharmokinetic profile (e.g., half life, clearance, metabolism, and excretion), dosing schedule s, and cost. Table 1 describes some of the more commonly used NSAID s. However, choice of NSAIDs is most often based on the desired dosing interval, determined by a drug 's half life. NSAID s with a short or medium half life are typicall y prescribed for clients who can vary the dosage according to severity of symptoms (i.e., decrease the frequency when doing well or increase MAY 1998, VOL. 46, NO.5 • When taken in low doses, salicylates have a short half life; when taken in medium to high doses, they have a medium half life. Adapted from Conaway (1995) the frequency when symptoms worsen). NSAIDs with a long half life are taken once daily and are often chosen to ensure compliance in forgetful clients or to obtain sustained drug levels in clients with significant pain or inflammation (Conaway, 1995) . Table 2 depicts the half lives of commonly used NSAIDs.
NSAIDs are used with caution in clients with a history of hypersensitivity to NSAIDs, including aspirin, as cross sensitivity may occur among different structural derivatives. NSAIDs are contraindicated in clients with a history of pulmonary or anaphylactoid manifestations of hypersensitivity associated with prior NSAID use (Herfindal, 1992) .
ADVERSE EFFECTS Gastrointestinal (GI) Problems
Although the use of NSAIDs is relatively safe, it is not without adverse effects. Some of the effects may be 255 severe in certain populations. Ninety-eight percent of all reported side effects with NSAID use are gastrointestinal. GI effects of NSAIDs are responsible for approximately 40% of hospital admissions among individuals with arthritis. NSAID gastropathy (i.e., gastric and duodenal mucosal lesions) is possibly the most serious drug side effect in the United States, leading to an estimated 15,000 to 20,000 deaths annually (Health Management Bulletin, 1997) . All NSAIDs may produce adverse gastrointestinal effects including indigestion, nausea, dyspepsia, diarrhea, constipation, and gastritis. Severe effects include GI ulceration , perforation, and bleeding . Although the non-acetylated salicylates (i.e., salsalate, choline salicylate ) have been associated with a lower incidence of gastric bleeding, no NSAID is completel y free of gastric injury risk when taken on a chronic basis.
The prevalence of gastric and duodenal ulcers averages 10% to 30% among chronic NSAID users (Hirschowitz, 1997) . Ulceration, perforation, and hemorrhage can occur without warning signs. The proposed mechanism of GI injury includes local irritation, inhibition of prostaglandin synthesis (prostaglandins inhibit gastric acid secretion), decreased availability of sulfhydryl donors (required for prostaglandin receptor activation), and inhibition of platelet aggregation (Herfindal, 1992) .
Factors related to increased risk of GI complication s include a history of peptic ulcer disease and/or GI bleeding, advanced age (over 60 years), duration of therapy (highest risk in the first 90 days of therapy), concomitant corticosteroid therapy, and clients with concomitant diseases such as congestive heart failure, diabetes mellitus, hypertension, etc. Other possible risk factors include smoking, alcohol use, presence of H. pylori, and being female (Health Management Bulletin, 1997) .
Recommendations for high risk clients include beginning therapy with low dose NSAIDs . Although usually recommended, advising clients to take NSAIDs with food is generally of little benefit (Hirschowitz , 1997) . According to most studies, enteric coated products do not change the ulcer rate. Use oftopical NSAIDs (e.g., Aspercream) circumvents GI injury. Rectal suppositories act systemically and cause the same ulcer rate, as well as rectal ulcers. Use of H 2 blockers with NSAIDs can prevent formation of duodenal ulcers and help heal gastric ulcers . Their use will not prevent gastric ulcers. Because gastric ulcers may be three to four times more common than duodenal ulcers among NSAID users, H 2 blockade alone does not constitute an adequate preventive treatment (Conaway, 1995) . In fact, a recent study concluded prophylaxis with antacids and H 2 antagonists is of questionable value and may suppress warning signs 256 which would lead to discontinuation or change of the offending NSAID (Singh, 1995) .
Misoprostol (Cytotec) is a synthetic prostaglandin analog with antisecretory and cytoprotective effects. When used while clients are taking NSAIDs, it will prevent both gastric and duodenal ulcers. Some studies show healing in ulcers of individuals who took misoprostol while continuing aspirin. Misoprostol also reduces the frequency of serious gastroduodenal complications such as perforation, hemorrh age, obstruction, and death . Therefore, use of misoprostol is indicated for clients at high risk for developing gastric ulceration (history of GI ulcers) or at high risk for developing complications (bleeding, perforations) from NSAID induced ulcers (elderly clients or clients with debilitating disease).
The most common side effects of misoprostol are dose related and include self limiting diarrhea in 5% to 40% of clients, abdominal pain , nausea, gas, and headaches. Halving the normal dose of 200 mg four times daily may decrease the incidence of adverse effects and seems to work just as well. Misoprostol is expensive and increases the cost of NSAID therapy significantly. It is contraindicated in pregnant women and in women of child bearing age unless adequate birth control is practiced, due to its ability to induce uterine contraction s (Herfindal, 1992) . A safer NSAID was approved by the U.S. Food & Drug Administration in January 1998. The drug, Arthrotec, consists of diclofenac (enteric coated) wrapped in 200 ug of misoprostol in one pill at a reasonable price. It is presently available in 40 countries, including the United Kingdom and Canada . Its success in those countries in a very short time is unequaled, as it combines NSAID efficacy with improved GI mucosal safety (McMillen, unpublished data).
Renal Effects
Renal effects are another side effect of NSAIDs and are related to the antiprostaglandin effect. NSAIDs block renal prostaglandins, thereby decreasing renal blood flow. Therefore , elderly client s (>60 years) are at risk as they already have slightly diminished renal blood flow. Also clients with renal impairment (including congestive heart failure, cirrho sis, and volume or water depletion) are at risk for renal insufficiency (Health Management Bulletin, 1997) .
Because normal renal function depends at least partially on prostaglandin synthesis, the administration of agents that inhibit prostaglandin synthesis (i.e., NSAIDs) may induce renal injury. Vasodilatory prostaglandins are released in response to the vasoconstriction produced by angiotensin II in clients with congestive heart failure, intravascular volume contraction, or on chronic diuretic therapy. When this compensatory mechanism is blocked, renal blood flow and glomerular filtration rate are reduced and secondary ischemia may occur. NSAID induced reduction in renal blood flow also may raise sodium reabsorption, resulting in edema and possible interference with antihypertensive therapy.
In clients with hypertension, NSAIDs can increase sodium retention which can lead to peripheral edema and also can precipitate heart failure in clients with impaired left ventricular function . NSAID s also are capable of interfering with pota ssium excretion in clients taking potassium sparing diuretics or in clients with hypoaldosteronemic conditions such as diabetes mellitus. When NSAIDs are used in clients with such conditions, renal prostaglandin synthesis is impaired to some degree, resulting in an unopposed renal vasoconstriction. Consequently, a decrea se in creatinine clearance occurs , resulting in elevated blood urea nitrogen (BUN) level s and creatinine levels. This type of impaired renal function is reversible with NSAID discontinuation (Conaway, 1995) . Recommendations for clients at risk for renal problems include evaluating renal function at baseline , 1 week after starting therapy and every 3 months during chronic therapy with NSAIDs . NSAID s with a short half life reach steadystate serum levels within 1 week . Thus, BUN and creatinine levels can be evaluated quickly. NSAIDs with a longer half life should be evaluated at 2 week s. The client also should be evaluated for the development of pedal edema , rales , and elevated blood pressure . It may be practical to stop the NSAID if the BUN or creatinine levels are > 20% above baseline (Conaway, 1995) . Other clients at risk for renal problems are individuals with systemic lupus erythematosus (SLE), congestive heart failure , hepatic dysfunction, and clients using concomitant nephrotoxic drugs .
Hepatic Effects
Serious hepatic injury (marked transaminase elevation or clinical hepatitis) is rare but can occur with virtually any NSAID (perhaps 1 in 100,000 to 300,000 prescriptions). When it does occur, it is not a prostaglandin mediated reaction but a hypersensitivity phenomenon. Approximately 15% of clients develop marginally elevated liver enzymes , most of which are not clinically significant. The most common problems seen are mild hepatic dysfunction, hepatitis (especially in clients with SLE and RA), and jaundice. Fatal liver damage is rare. The recommendation is to monitor liver functions at baseline and at 3 months, as most hepatic side effects occur within this MAY 1998, VOL. 46, NO.5 time. If either the alanine aminotransferase (ALT) or aspartate aminotran sferase (AST) levels rise to two or three times normal, the NSAID should be stopped and liver function allowed to return to normal.
Hematologic Effects
All NSAIDs, except the non-acetylated salicylates (e.g., Salsalate), sodium salicylate and choline magnesium trisalicylate, inhibit platelet aggregation , thereby prolonging bleeding time and interfering with appropriate function by affecting platelet function . An irreversible anti-platelet effect occurs with aspirin (lasts 7 to 10 days). All other NSAIDs produce a reversible inhibition of platelet aggregation, which persists while the drug is in the systemic circulation. Therefore , with the exception of the non-acetylated salicylates noted above, NSAIDs are relatively contraindicated in clients with coagulation defects, individuals with a history of ulcers, and persons currently receiving anticoagulation therapy. Leukopenia , thrombocytopenia, and agranulocytosis may occur rarely and are generally reversible.
Recommendations include periodic assessment of hematologic indice s (i.e., hemoglobin, hematocrit, red blood cell count, white blood cell count, and platelets) to detect problems earl y on and prevent adverse effects. Also, due to prolonged bleeding time, a general rule is to stop NSAIDs five times the half life before surgery. For example, if a client was taking etodolac (with a short half life of approximately 7.3 hours), it would be advisable to discontinue the medicine approximately 36.5 hours (7.3 hours X 5) before surgery. NSAIDs with long half lives must be discontinued 7 days prior to surgery; less time is needed for NSAIDs with short half lives (Herfindal, 1992) (See Table 2 .)
Miscellaneous Effects
NSAIDs can affect anti-hypertensive therapy by raising the supine blood pressure approximately 5 mm Hg. NSAIDs also blunt the effectiveness of antihypertensive therapy, particularly beta blockers and less so with diuretics and vasodilators (Johnson , 1994) . Central nervous system effects are seen primarily with indomethacin (Indocin) and include headache, confusion, and dizziness. Indocin also can aggravate psychiatric conditions, epilepsy, and Parkinson's disease. Aspirin has caused tinnitus at high doses. This is eliminated with a decreased dose. NSAID use can worsen asthma in some individuals, particularly those with asthma, rhinitis, and nasal polyp syndrome, "the aspirin triad." In these clients, severe and even potentially fatal bronchospasms after taking aspirin or other NSAIDs have been reported. Although rarely, piroxicam (Feldene) has caused permanent hearing loss. Tolmetin sodium (Tolectin) and diclofenac (Voltaren) have aggravated symptoms of congestive heart failure. Sulindac (Clinoril) has caused acute pancreatitis, though this is rare.
DRUG INTERACTIONS
Drug interactions of importance include those with anticoagulants, sufonylureas, corticosteroids, and uricosuric agents (probenicid and sulfinpyrazone). With antihypertensive therapy, blood pressure must be monitored . When used with potassium sparing diuretics, serum potassium needs to be monitored. Because NSAIDs are highly protein bound, other highly protein bound drugs, including warfarin, tolbutamide, and phenytoin, may be 258 displaced (Skeith, 1990; Stewart, 1990) . Table 3 describes possible NSAID-drug interactions.
CONCLUSION
In just over 20 years, an impressive array of NSAIDs has been developed which are well known for their analgesic and antiinflammatory properties. While not the only therapy for a wide range of diseases, NSAIDs have long been a reliable treatment in battling pain and inflammation and in helping clients maintain a high quality of life. In combination with proper diet, exercise, and behavioral approaches to help deal with chronic pain, NSAIDs can help clients function with greater comfort in their work activities and recreational pursuits.
Of particular promise is the development of a PGHS-
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2 specific inhibitor. These drugs, when readily available, should offer efficacy equal to today' s most potent NSAIDs with minimal side effects, including gastric safety.
Because the nurse at the worksite influ ence s employee health status, this information will help in counseling employee s, encouraging follow through with appropriate dosing, and watching for side effects. The nurse practitioner should be able to fully understand rationale for treatment and be able to differentiate the features and benefits that specific NSAIDs can provide. With proper treatment and monitoring, NSAIDs can improve functioning and quality of life.
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Non-steroidal antiinflammatory drugs (NSAIDs) are among the most frequently prescribed medications and are used primarily to control pain , stiffness, and reduce inflammation .
One of the most common adverse effects of NSAID therapy is gastrointestinal (GI) problems, specifically indigestion, nausea, dyspepsia, diarrhea, constipation, and gastritis.
Considerations in chronic pain management include non-pharmacologic treatment options (Le., physical therapy, behavioral therapy, etc.), use of misoprostol for clients at high risk for NSAID induced GI problems , and monitoring blood and urine every 3 months to 1 year with chronic NSAID therapy to detect liver, kidney, and hematologic problems. Current research is focused on development of a prostaglandin H synthetase (PGHS-2) inhibitor which should offer efficacy equal to the most potent NSAIDs with minimal side effects, including gastric safety.
